Radiotherapy duration

radiotherapy tolerance tests

SHORT VERSION

The duration of the entire radiotherapy treatment and the length of each session vary in function of the tumor location and the modality. The number of treatment sessions ranges from one to forty sessions, spread over a period of 1 to 8 weeks, and each session lasts between 10 and 40 minutes (for the most complex techniques, such as stereotactic radiotherapy).

The length of a radiation therapy session depends on the type of technique used. With standard radiotherapy techniques, such as conformal radiotherapy, the session lasts about 10 minutes. This includes the set-up time and the irradiation time. With special techniques, such as stereotactic radiotherapy, a session can last 30 to 40 minutes.

The duration of the entire radiotherapy treatment depends on the indication (e.g. objective sought, tumor location). It can vary from one single session to 40 sessions, for example for prostate tumor radiotherapy.

Radiotherapy hair loss

Notez cet post

FIRST TESTS TO PREDICT A PATIENT’S RADIOSENSITIVITY

NovaGray develops and commercializes the first radiotherapy tolerance tests for patients treated for breast or prostate cancer.

Performed before the start of radiotherapy with a simple blood draw, the tests assess the patients’ individual radiosensitivity and determine their risk of developing late complications after radiotherapy.

WHY DO A RADIOSENSITIVITY TEST?

Knowing a patient’s individual radiosensitivity is important information that can help:

  • Reassure the patient in preparation for radiotherapy
  • Guide physicians in choosing the most appropriate treatment plan
  • Adapt patient follow-up after radiotherapy

Team NovaGray

NovaGray develops radiotherapy tolerance tests for breast and prostate cancer patients. NovaGray's mission is to help personalize cancer treatment by assessing each patient's individual sensitivity before starting radiotherapy. NovaGray technology has been validated by multi-center prospective clinical trials. NovaGray tests are recommended by the French Society of Radiation Oncology (SFRO).